Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 14/20 | 0.69 |
| ▸ | FAAH | O00519 | 10/20 | 0.59 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.59 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14057654 | 0.87 | KDM4E (0.63) | CES1FAAHMAPT | |
| SCHEMBL3380712 | 0.85 | HDAC1 (0.58) | CES1MAPTRXFP1 | |
| SCHEMBL2418294 | 0.83 | CTNNB1 (0.55) | CES1MAPTRXFP1 | |
| SCHEMBL13883837 | 0.82 | CTNNB1 (0.54) | CES1 | |
| SCHEMBL2161875 | 0.82 | CES1 (1.00) | CES1FAAHNCEH1MAPTRXFP1 | |
| SCHEMBL2161912 | 0.81 | CES1 (0.65) | CES1FAAHNCEH1 | |
| SCHEMBL1254915 | 0.81 | LMNA (0.63) | FAAH | |
| SCHEMBL6242788 | 0.81 | CTNNB1 (0.53) | CES1 | |
| SCHEMBL1254914 | 0.81 | LMNA (0.63) | FAAH | |
| SCHEMBL9440127 | 0.81 | LMNA (0.63) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-7858611-B2 | Neurogenesis by modulating angiotensin | BRAINCELLS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2258357-A2 | Neurogenesis with acetylcholinesterase inhibitor | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258359-A2 | Neurogenesis by muscarinic receptor modulation with sabcomelin | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258358-A2 | Neurogenesis with acetylcholinesterase inhibitor | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100216734-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216805-A1 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS | BRAINCELLS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100120842-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7678363-B2 | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs | BRAINCELLS INC (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2007134136-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | CES1 2253/4885FAAH 1060/4885NCEH1 751/4885 |
| US-20100120842-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | CES1 2253/4885FAAH 1060/4885NCEH1 751/4885 |
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR5A, HTR6, GAP43 | CES1 4532/4885FAAH 439/4885NCEH1 1825/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | CES1 3727/4885FAAH 1716/4885NCEH1 493/4885 |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | CES1 2379/4885FAAH 606/4885NCEH1 1548/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | CES1 3125/4885FAAH 1051/4885NCEH1 1034/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | CES1 4575/4885FAAH 739/4885NCEH1 2101/4885 |
| US-20100216734-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, NGF | CES1 4327/4885FAAH 477/4885NCEH1 1245/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | CES1 2253/4885FAAH 1060/4885NCEH1 751/4885 |
| US-20100216805-A1 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS | GAP43, DCX, CHAT | CES1 4182/4885FAAH 1413/4885NCEH1 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.